In patients with advanced epithelial ovarian cancer, first-line maintenance therapy with PARP inhibitors was associated with a progression-free survival benefit compared with standard chemotherapy ...

Poly(ADP-ribose) polymerase (PARP) inhibitors should be considered a treatment option for patients with uterine leiomyosarcomas harboring BRCA2 deep deletions, researchers advised. PARP inhibitors are ...

Olaparib is the only PARP inhibitor that significantly improves overall survival in PSROC, distinguishing it from other PARP inhibitors. All four PARP inhibitors enhance progression-free survival, ...

Please provide your email address to receive an email when new articles are posted on . Nearly half of men with metastatic castration-resistant prostate cancer eligible for PARP inhibitors do not get ...

Ovarian cancer in adolescents and young adults compared with older women: Prognostic factors, demographic characteristics, and survival along 2 decades in the US. This is an ASCO Meeting Abstract from ...

The cancer drugs called PARP inhibitors have a puzzling reputation: even though they are treatment mainstays for multiple forms of cancer, they can damage cancer-killing T cells and disrupt the ...

Please provide your email address to receive an email when new articles are posted on . Saruparib at 60 mg/day demonstrated deep, durable responses with a high response rate and tumor reduction in ...